GlycoBac

GlycoBac is a private, pre-revenue biotech firm developing an engineered insect cell production platform to overcome the glycosylation limitations of traditional insect and mammalian systems for biologics manufacturing. Its proprietary Sf-RVN cell line, distributed in partnership with MilliporeSigma, offers a safer alternative for vaccine and gene therapy vector production by being resistant to problematic Sf-rhabdovirus variants. The company's focus is on providing the platform, tools, and services to enable other entities to produce more effective and safer protein therapeutics, positioning itself as an enabling technology provider rather than a drug developer.

Glycoengineered baculovirus-insect cell platform for producing biologics with human-like glycosylation. Includes proprietary Sf-RVN cell lines engineered for proper glycosylation and resistance to Sf-rhabdovirus, along with associated vectors and plasmids.

GlycoBac competes with established mammalian CDMOs and platform companies, as well as other groups engineering alternative host systems (yeast, plants, other insect cells) for human glycosylation. Its differentiation lies in its specific focus on solving both glycosylation and viral contamination issues within the baculovirus-insect cell system.